Neuroendocrine Tumor Treatment Market By Treatment Type (Somatostatin Analogues, Peptide Receptor Radionuclide Therapy, Targeted Therapies, Chemotherapy, Liver-Directed Therapies, Oral Somatostatin-Pathway Therapies, Other Treatments); By Tumor Type (Gastroenteropancreatic NETs, Pancreatic NETs, Extra-Pancreatic NETs, Lung NETs, Poorly Differentiated Neuroendocrine Carcinomas, Others); By SSTR Status (SSTR-Positive NETs, SSTR-Negative NETs); By End User (Hospitals, Specialty Oncology Centers, Nuclear Medicine Centers, Academic & Research Institutes); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Neuroendocrine Tumor Treatment Market: PRRT Expansion, Cabozantinib Approval, and SSTR Imaging Redraw Long-Term NET Care

The Global Neuroendocrine Tumor (NET) Treatment Market was valued at USD 2.59 billion in 2025 and is projected to reach USD 4.12 billion by 2032, registering a robust CAGR of 6.82%, according to Strategic Market Research.

 

Neuroendocrine tumor treatment is shifting toward long-term disease control because incidence and prevalence continue to rise. A SEER-based JAMA Network Open analysis identified 145,447 neuroendocrine neoplasm cases in the U.S. from 1975 to 2021. Age-adjusted incidence increased 5.2-fold from 1.64 per 100,000 in 1975 to 8.52 per 100,000 in 2021. Estimated 20-year limited-duration prevalence reached 248,546 people living with neuroendocrine neoplasms as of January 1, 2021. This expanding population increases demand for repeated staging, somatostatin receptor imaging, systemic therapy, peptide receptor radionuclide therapy, liver-directed procedures, and surveillance at specialist centers.

 

Survival outcomes are a key determinant of the economic structure of neuroendocrine tumor care. Median overall survival in the U.S. analysis was 11.8 years across all neuroendocrine neoplasms. Well-differentiated NETs had median survival of 16.8 years, while poorly differentiated neuroendocrine carcinomas had median survival of only 10 months. Localized disease had median survival above 30 years, while distant-stage disease had median survival of 1.2 years overall. Well-differentiated NETs support a chronic treatment model built around control, sequencing, and surveillance. Poorly differentiated NECs remain closer to high-urgency oncology, where survival gains depend on stronger systemic regimens and clinical trial progress.

 

Diagnosed Prevalence Is Expanding the Treated NET Population

The increasing incidence of neuroendocrine tumors reflects improvements in disease recognition, advanced imaging adoption, broader endoscopic evaluation, enhanced pathology classification, and more consistent registry reporting. Although NETs remain individually uncommon across specific primary sites, the growing diagnosed population has become clinically significant enough to influence oncology infrastructure, therapeutic development, nuclear medicine capacity, and payer strategy.

Gastroenteropancreatic neuroendocrine tumors represent the most important treated population in the United States. SEER data indicate an incidence of 4.27 per 100,000 for GEP-NETs, with small intestine NETs at 1.41 per 100,000, pancreatic NETs at 1.31 per 100,000, rectal NETs at 1.22 per 100,000, and appendiceal NETs at 1.20 per 100,000. Lung NETs demonstrate an incidence of 1.40 per 100,000. GEP-NETs have the strongest relevance for peptide receptor radionuclide therapy because somatostatin receptor expression enables identification and treatment through radioligand-based approaches. Pancreatic NETs remain commercially important due to the availability of multiple systemic treatment options, including targeted therapies and chemotherapy. Lung NETs require more differentiated clinical positioning, as typical carcinoid, atypical carcinoid, large-cell neuroendocrine carcinoma, and small-cell neuroendocrine malignancies follow distinct therapeutic pathways.

England shows a similar pattern of diagnostic expansion. A national registration analysis found that age-adjusted NEN incidence increased 3.7-fold from 2.35 per 100,000 in 1995 to 8.61 per 100,000 in 2018. The highest 2018 site-specific incidence rates were lung at 1.47 per 100,000, small intestine at 1.46 per 100,000, pancreas at 1.00 per 100,000, and appendix at 0.95 per 100,000. Cancer Research UK states that around 4,100 people are diagnosed with neuroendocrine cancer each year in England, with around 40% beginning in the digestive system and around 20% beginning in the lung. These figures support continued need for NET centers, specialist imaging, multidisciplinary review, and treatment sequencing infrastructure.

European treatment demand is concentrated in specialist-center networks. ENETS registry analysis of 10,102 patients across seven national registries reported major primary sites in the pancreas and small intestine, with a high share of patients diagnosed at advanced stage. Treatment exposure in the registry included surgery, somatostatin analogues, chemotherapy, PRRT, and targeted therapies. Surgery remains the leading curative option for localized disease, but advanced and metastatic NET care is increasingly shaped by long-term systemic treatment, radioligand access, and repeated imaging.

 

Site, Grade, and SSTR Status Decide Treatment Value

NET treatment requires a differentiated clinical approach rather than a uniform oncology framework. WHO/IARC classifications distinguish well-differentiated neuroendocrine tumors (NETs), poorly differentiated neuroendocrine carcinomas (NECs), and mixed neuroendocrine–non-neuroendocrine neoplasms. Factors including tumor differentiation, grade, Ki-67 index, primary site, disease stage, progression rate, tumor burden, and somatostatin receptor expression play a critical role in treatment selection, prognosis assessment, reimbursement considerations, and commercial opportunity.

Well-differentiated, SSTR-positive GEP-NETs offer the most structured treatment pathway. Patients may move from surgery or observation into somatostatin analogues, then into PRRT, cabozantinib, everolimus, sunitinib, capecitabine-temozolomide, liver-directed therapy, or clinical trials depending on progression pattern. Poorly differentiated NECs require a different strategy because faster growth and shorter survival make platinum chemotherapy, immunotherapy combinations, and experimental regimens more relevant than chronic-control approaches. Mixed tumors create additional treatment complexity because both neuroendocrine and non-neuroendocrine components may influence regimen selection.

Somatostatin analogues remain the foundation of many well-differentiated NET treatment pathways. Long-acting octreotide and lanreotide support hormone control and disease stabilization in selected SSTR-positive tumors. Their role also shapes later treatment conversion because progression after somatostatin analogue therapy can move patients toward PRRT, targeted therapy, chemotherapy, or trial-based combinations. In commercial terms, these products create the baseline treated population from which higher-value sequencing decisions emerge.

 

PRRT Is Joining Imaging, Therapy, and Nuclear Medicine Capacity

Peptide receptor radionuclide therapy represents one of the most prominent value-expansion areas in neuroendocrine tumor treatment. Its use depends on accurate identification of somatostatin receptor–positive disease, access to PET imaging or scintigraphy, reliable isotope availability, nuclear medicine infrastructure, renal-protection protocols, infusion capacity, and longitudinal imaging follow-up. Hospitals and specialist centers equipped with these capabilities are better positioned to translate diagnostic confirmation into timely therapeutic intervention than facilities relying primarily on conventional oncology pathways.

Lutathera remains the main commercial reference point for PRRT in NETs. In April 2024, the FDA approved lutetium Lu 177 dotatate for pediatric patients aged 12 years and older with SSTR-positive GEP-NETs, expanding the earlier adult indication. Pediatric patient volume is limited, but the label expansion reinforces PRRT as an established treatment platform across age groups when SSTR-positive disease is confirmed.

Evidence supporting earlier-line PRRT use is becoming increasingly relevant to the future treatment landscape for neuroendocrine tumors. NCI reported that the NETTER-2 trial showed Lu 177-dotatate plus octreotide delayed growth of advanced digestive-system NETs when used as initial treatment. The trial focused on advanced, well-differentiated, higher-grade GEP-NETs that had not yet received treatment. Earlier-line use would increase the strategic importance of PRRT because treatment decisions would move closer to diagnosis rather than later progression.

European regulatory positioning remains more conservative. EMA noted that Advanced Accelerator Applications withdrew an application in May 2025 to expand Lutathera use to adults with newly diagnosed GEP-NETs. Lutathera remains authorized in the EU for adults with unresectable or metastatic GEP-NETs that are not responding to treatment, but broader first-line expansion will require stronger regulatory acceptance. PRRT adoption will therefore depend not only on clinical enthusiasm but also on label scope, evidence review, reimbursement, and treatment-center capacity.

Diagnostic radiopharmaceuticals are becoming part of treatment-market access. FDA first-generic activity supports wider imaging availability. In 2024, FDA listed the first generic approval for Indium In-111 Pentetreotide Kit for scintigraphic localization of primary and metastatic NETs bearing somatostatin receptors. In 2025, FDA listed a first generic approval for Gallium Ga 68 Edotreotide Injection for PET localization of SSTR-positive NETs in adults and pediatric patients. These agents support patient identification, staging, treatment planning, and PRRT eligibility, making imaging access a practical gatekeeper for therapy adoption.

 

Cabozantinib Strengthens the Post-Progression Segment

Cabozantinib represents one of the most significant recent targeted-therapy developments in neuroendocrine tumor (NET) management. March 26, 2025, the FDA approved cabozantinib for adults and pediatric patients aged 12 years and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic NETs and extra-pancreatic NETs. The approval gave clinicians a new systemic option across pNET and epNET populations after prior therapy.

The CABINET trial findings provided strong clinical and commercial relevance for this approval. NEJM-reported results showed median progression-free survival of 13.8 months with cabozantinib versus 4.4 months with placebo in pancreatic NETs. In extra-pancreatic NETs, median progression-free survival was 8.4 months with cabozantinib versus 3.9 months with placebo. Progression delay matters in NET care because many patients move through multi-year treatment pathways where disease control, symptom burden, toxicity, and timing of next therapy all affect clinical decisions.

Cabozantinib is also gaining relevance within European neuroendocrine tumor treatment strategy. In July 2025, Ipsen reported European Commission approval for cabozantinib in adult patients with unresectable or metastatic, well-differentiated pancreatic NETs or extra-pancreatic NETs who experienced disease progression after at least one prior systemic therapy other than somatostatin analogues. NICE is evaluating cabozantinib for advanced pancreatic or extra-pancreatic NETs that progressed after systemic treatment, with publication timing still listed as to be confirmed. UK adoption will depend on cost-effectiveness, sequence placement, eligible patient numbers, and clinical value after prior therapy.

Cabozantinib is increasing competitive pressure on established targeted therapies. Everolimus and sunitinib remain important, especially in pancreatic NETs, but post-progression treatment has become more contested. Clinicians and payers will increasingly ask where each therapy fits after somatostatin analogues, PRRT, prior targeted therapy, chemotherapy, or liver-directed treatment. Sequencing evidence will carry more weight than simple product availability.

 

Oral Somatostatin-Pathway Drugs Could Change Chronic Symptom Control

Long-acting injectable somatostatin analogues dominate chronic symptom-control workflows, but oral therapies could change convenience, clinic scheduling, and patient adherence if late-stage evidence supports use. Crinetics’ paltusotine is the key asset to watch in this area. The company states that paltusotine is in clinical development for carcinoid syndrome associated with NETs through a global Phase 3 pivotal program. Its Phase 3 CAREFNDR study builds on earlier data showing reductions in flushing episodes and bowel movements.

Vertex’s July 2026 agreement to acquire Crinetics for about USD 10 billion increased strategic attention around oral somatostatin-pathway assets. The deal is not a NET-only transaction because Crinetics also has approved and pipeline assets in broader endocrinology. For NET care, the relevant question is whether an oral, once-daily approach can compete with or complement injectable somatostatin analogues in carcinoid syndrome.

An effective oral therapy would compete on practical care delivery rather than broad tumor control. Injectable somatostatin analogues require recurring administration, depot logistics, pharmacy coordination, and scheduled visits. Oral treatment could reduce administration friction for selected patients, but adoption would still depend on symptom-control durability, tolerability, payer acceptance, and physician confidence against established depot products.

 

Regional Growth Depends on Diagnosis, Imaging, and Reimbursement

The U.S. is the highest-value NET treatment market because advanced imaging, PRRT capacity, and specialist referral networks are already embedded in tertiary oncology care. FDA approvals can move rapidly into practice when SSTR-PET imaging, nuclear medicine infrastructure, and multidisciplinary NET programs are available. Lutathera pediatric expansion and cabozantinib approval for pNET and epNET are therefore entering a market with established treatment sequencing and trial access.

Europe has strong NET registry infrastructure but treatment uptake remains country-specific. ENETS supports specialist referral and multidisciplinary care across the region. Reimbursement decisions remain the main adoption barrier. The UK NICE review of cabozantinib shows that regulatory approval does not guarantee routine access. Germany, France, Spain, Italy, and the UK remain priority markets because NET treatment is concentrated in specialist centers with nuclear medicine services, expert pathology, and formal multidisciplinary tumor boards.

Asia Pacific is experiencing increasing diagnosis of neuroendocrine neoplasms (NENs), although access to advanced treatment remains uneven across countries. Evidence from China indicates a rising incidence of NENs, with the lung, pancreas, stomach, and rectum among the most frequently reported primary sites. Taiwan registry data show that NET incidence increased from 0.244 per 100,000 in 1996 to 3.162 per 100,000 in 2015, with the rectum identified as the most common site. In Japan, hospital-based registry evidence documented 33,215 NEN cases between 2009 and 2015, with the rectum reported as the most frequent NET site and the lung representing a major site for neuroendocrine carcinoma (NEC). These regional patterns suggest growing endoscopy-associated detection, increasing clinical attention to rectal NET management, and the development of country-specific diagnostic and treatment pathways rather than a direct replication of Western market demand.

Australia further illustrates how disease coding and registry definitions can influence market interpretation. The Australian Institute of Health and Welfare reported that NEN diagnoses more than doubled, rising from 2,123 cases in 2000 to 4,693 cases in 2020. During the same period, overall 5-year relative survival improved from 39% in 2006–2010 to 52% in 2016–2020. Higher diagnosis rates and improving survival are likely to expand demand for diagnostic evaluation, treatment sequencing, and long-term disease monitoring. However, comparisons with U.S. or England datasets should be interpreted cautiously because registry definitions, case inclusion criteria, and disease classification practices differ across reporting systems.

 

Competitive Positioning Is Centered on Sequencing Control

Novartis holds the strongest radioligand position through Lutathera and its wider radiopharmaceutical platform. Its advantage depends on SSTR-positive patient identification, referral pathways, isotope supply, nuclear medicine capacity, and payer coverage. Earlier-line expansion would improve its position, but European regulatory caution shows that broader use must be backed by acceptable evidence.

Exelixis and Ipsen gained stronger NET positioning through cabozantinib. CABINET data and 2025 approvals place Cabometyx as a meaningful post-progression option across pNET and epNET. Uptake will depend on sequence placement after somatostatin analogues, PRRT, everolimus, sunitinib, and chemotherapy. Safety management, payer controls, and physician comfort with long-term use will affect prescribing behavior.

Crinetics brings pressure to the symptom-control segment rather than the tumor-control segment. Paltusotine’s NET relevance sits in carcinoid syndrome, where oral treatment could reduce dependence on injectable workflows if Phase 3 data are strong. Vertex’s acquisition improves potential commercial reach, but clinical differentiation against long-acting injectable somatostatin analogues remains the deciding factor.

Older treatment modalities will continue to retain clearly defined clinical roles. Everolimus, sunitinib, capecitabine-temozolomide, platinum-based chemotherapy, and liver-directed therapies remain relevant because NET treatment varies by site, grade, tumor pace, liver burden, and prior therapy. Drug competition will be decided by sequence fit, not by one product class replacing all existing approaches.

 

High-Grade NEC Remains the Hardest Treatment Segment

Poorly differentiated NECs create the largest clinical gap in neuroendocrine cancer care. Survival remains far shorter than in well-differentiated NETs, and treatment is still closer to aggressive carcinoma management than chronic NET control. The U.S. survival split is severe: median survival of 16.8 years for well-differentiated NETs versus 10 months for poorly differentiated NECs.

Clinical development in high-grade disease is moving toward combinations because single-agent activity has been limited. Trials involving chemotherapy, immunotherapy, targeted agents, and virus-based approaches are being used to test whether aggressive neuroendocrine tumors can be made more responsive. In 2026, Sylvester researchers reported a Phase 1 trial testing Seneca Valley virus SVV-001 with nivolumab and ipilimumab in high-grade neuroendocrine neoplasms. Such programs are not near-term revenue drivers, but they mark the segment where survival improvement would carry the highest clinical value.

 

Analyst View

NET treatment is being reshaped by three commercial inflection points: earlier PRRT use, broader post-progression systemic therapy, and oral competition in somatostatin-pathway care.

PRRT has the strongest strategic value because it combines SSTR imaging, radiopharmaceutical supply, nuclear medicine capacity, treatment administration, and follow-up into a single revenue pathway. Expansion depends on scanner access, isotope availability, treatment-center throughput, and reimbursement for both imaging and therapy. Cabozantinib is the key recent systemic approval because it adds a treatment option after progression in both pNET and epNET, expanding the addressable post-SSA and post-targeted-therapy population. Oral somatostatin-pathway therapy is the main threat to depot SSA franchises. If Phase 3 data show comparable symptom control and acceptable tolerability, oral products could shift carcinoid syndrome treatment away from injection-based maintenance care.

 

Neuroendocrine Tumor (NET) Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 2.59 Billion
Revenue Forecast in 2032	USD 4.12 Billion
Overall Growth Rate	CAGR of 6.82% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Tumor Type, By SSTR Status, By End User, By Geography
By Treatment Type	Somatostatin Analogues, Peptide Receptor Radionuclide Therapy (PRRT), Targeted Therapies, Chemotherapy, Liver-Directed Therapies, Oral Somatostatin-Pathway Therapies, Other Treatments
By Tumor Type	Gastroenteropancreatic NETs, Pancreatic NETs, Extra-Pancreatic NETs, Lung NETs, Poorly Differentiated Neuroendocrine Carcinomas, Others
By SSTR Status	SSTR-Positive NETs, SSTR-Negative NETs
By End User	Hospitals, Specialty Oncology Centers, Nuclear Medicine Centers, Academic & Research Institutes
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising diagnosed NET prevalence Expanding PRRT adoption Increasing SSTR imaging availability
Customization Option	Available upon request